Treatment of acute myeloid leukaemia with a triple cytotoxic regime: DAT.
Twenty patients with acute myeloid leukaemia (AML) were treated with a combination of chemotherapy which included daunorubicin, cytosine arabino-side and 6-thioguanine (DAT). The complete remission rate was 85% and was achieved, in responsive cases, after an average of 2 courses of therapy. Patients remained in hospital for an average of 37.5 days during remission-induction therapy and 3.7 days per month thereafter. The median remission period was 48 weeks and median survival was 70 weeks. A disappointing feature was the high relapse rate. This feature of the results re-affirms the need for a more effective form of remission therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use*
D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin
Lancet. 1977 May 14;1(8020):1054
67510
Lancet. 1977 Mar 5;1(8010):497-9
65605
Semin Oncol. 1976 Sep;3(3):271-82
1068529
Tohoku J Exp Med. 1976;118 Suppl:217-25
1067159
Lancet. 1976 Sep 11;2(7985):574-5
60649
Lancet. 1975 Dec 13;2(7946):1200-1
53673
Lancet. 1975 Oct 4;2(7936):621-4
52000
Cancer. 1972 Dec;30(6):1572-82
4509106
Cancer Chemother Rep. 1975 May-Jun;59(3):537-45
1060509